Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

Albiglutide is a glucagon-like peptide-1 (GLP-1) mimetic generated by genetic fusion of a dipeptidyl peptidase-IV-resistant GLP-1 dimer to human albumin.

Albiglutide was designed to retain the therapeutic effects of native GLP-1 while extending its duration of action.

Who Took Part

According to the abstract, 39 subjects were involved.

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, single-blind and placebo-controlled study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In this single-blind Glucagon study one party knew the assignments and the other did not.

A placebo (an inactive look-alike) gave the Glucagon group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Area Under Curve, Blood Glucose, Glucagon-Like Peptide 1, Glycated Hemoglobin and Half-Life.

What This Means in Plain Language

The paper is a randomized, single-blind and placebo-controlled study of Glucagon in 39 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2009 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Glucagon compound page, all human trials.